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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Surveying the vast progress in Huntington’s disease research and a “blitz”
of clinical trials now in progress, a key scientific leader in the efforts has
predicted that they will produce treatments for the incurable neurological
disorder.
“I have every confidence that this batch of clinical candidates that are now
being tested are going to yield the first treatments for Huntington’s,” said
Robert Pacifici, Ph.D., the chief scientific officer for CHDI, the multimillion-dollar non-profit virtual HD biotech.
Dr. Pacifici’s remarks came in an interview on February 24 in Palm
Springs, CA, at the organization’s 11th Annual HD Therapeutics
Conference, sponsored by CHDI Foundation, Inc., the backer of the
initiative.
Nobody can foretell the result of a clinical trial, and Dr. Pacifici did not
specify a timeline for an effective treatment reaching the market. However,
he offered examples of the immense progress towards developing
treatments.
“It’s really frustrating for people, I know, to say, ‘That’s good news, that’s
good news, but where’s the treatment, where are the drugs?’” Dr. Pacifici
said. “The thing I would point to is that so many of the things we said were
going to happen actually have happened. And so many of the things that
have happened have actually yielded the outcome that we wanted.”
Dr. Pacifici cited three recent key advances: the ongoing research in
biomarkers (signals) to measure the efficacy of potential drugs’ in reducing
the harmful presence of abnormal huntingtin protein in brain cells; major
progress in identifying modifier genes that delay or hasten disease onset;
and the start of clinical trials.
The trials post the most “difficult” challenge in the process, he said.
“We want to make sure that we do things in a way that obviously is very
careful,” he said, explaining the primacy of drug safety. “The last thing we
want to do is harm anybody.”
Noting that the search for drugs has no guarantees, Dr. Pacifici
nevertheless concluded that these are “exciting times” for the community
of HD families, researchers, and supporters of the cause.
You can watch my interview with Dr. Pacifici in the video below.
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27:48

'Every confidence first Huntington's disease treatments' in the works from
Gene Veritas on Vimeo.
First Ionis patients safe
Until recent years, such good news seemed like a remote possibility for HD
Therapeutics Conference participants and, indeed, for the entire HD
community.
Because of the growing number of HD clinical trials and therefore greater
hope for effective treatments, Dr. Pacifici and fellow CHDI conference
organizers launched a new feature at this year’s conference, the “Clinical
Trials Update Blitz.” Representatives from four different trials presented
their latest news in 15-minute presentations.
The most anticipated update focused on the historic trial by Ionis
Pharmaceuticals, Inc., to attack the root cause of HD via gene-silencing.
Trial principal investigator Sarah Tabrizi, M.D., Ph.D., of University
College London reported that all patients in the very first cohort in the
Phase 1b/2a trial – aimed at testing primarily safety and tolerability –
completed the trial without incident.
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Dr. Sarah Tabrizi updating the historic Ionis gene-silencing trial (photo
by Gene Veritas)
The first group of participants received the first dosing of the drug, IONISRTTRX, in October 2015. They received three additional doses at 28-day
intervals and were monitored by trial administrators.
“We completed Cohort A, in London and Vancouver, four subjects, and the
DSMB [independent data safety monitoring review board] met and
allowed us to move to cohort B,” Dr. Tabrizi said. (A DSMB, a standard in
all clinical trials, halts a study if patient safety is threatened.)
Administrators of the Ionis trial are currently recruiting volunteers for
Cohort B, to be followed by Cohorts C and D, as outlined in the plans for
the experiment. In all, 36 patients will take part in Phase 1b/2a. If all
cohorts are successful, Ionis will seek approval for a full-blown, larger
Phase 2 trial to test drug efficacy.
For further background on the trial, watch Dr. Tabrizi’s update in the video
below.
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First Patients Safe in Ionis Trial for Huntington's Disease Treatment from
Gene Veritas on Vimeo
More than a disease
Drawing a record 325 participants from academia, the pharmaceutical
business, and the medical field, the conference highlighted cutting-edge
HD research, including the structure and function of the huntingtin
protein; the huntingtin gene and the human genome; potential genesilencing treatments; restoration of cell health; and ways to measure
clinical trial outcomes.
Although highly dedicated to HD research, many of the non-physician
scientists have little if any contact with HD families. This has prompted
CHDI to open each conference with a keynote by a representative of the
HD community to drive home the human reality of the disease and the
urgent need for treatments. (I keynoted the 2011 meeting.)
This year Astri Arnesen and Svein Olaf Olsen, a married couple who have
led the HD cause in their native Norway and in the European Huntington
Association, delivered a powerful keynote about HD and marital
commitment, denial, genetic testing, and raising a family. They titled their
presentation “HD – more than a disease!”
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Astri and Svein Olaf received a standing ovation.
I will explore their story and provide an overview of the key scientific
findings in a second report on the conference.

Svein Olaf Olsen (left) and Astri Arnesen (photo by Gene Veritas)
An upbeat mood
As in past years, the CHDI meeting moved me profoundly.
I identified with the many difficult feelings and experiences recounted by
Astri and Svein Olaf.
Once again, the scientists’ presentations reminded me of HD’s devastation
of the brain – and of my vulnerability as a carrier of the HD mutation.
But this was a very upbeat conference. I had never spoken before to Dr.
Tabrizi, but we hugged as if we were old friends after I congratulated her
on the initial clinical trial report. The HD community has waited so long
for such news!
Later, after I worked late into the evening on this article and missed the
buffet dinner, Jerry Turner, the CHDI staffer in charge of conference
logistics, arranged for a care plate of sumptuous leftovers from the kitchen
of the Parker hotel, the gracious host of the conference.
I toasted to the success of the Ionis clinical trial and to CHDI’s
commitment to the project with Doug Macdonald, Ph.D., CHDI’s director
of drug discovery and development and its point man on gene-silencing.
As I told another scientist, I look forward to the day when we can all toast
the discovery of an effective treatment.
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 11:36 AM
Labels: biomarkers , brain , CHDI , clinical trials , gene-silencing , huntingtin ,
Huntington's disease , Ionis Pharmaceuticals , modifier gene , neurological , onset ,
Robert Pacifici , Sarah Tabrizi , treatments
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Anonymous said...
Gene, thank you so much for your updates. As an HD mutation
carrier, I always look forward to these. I admire your dedication
to get your article out asap, so much that you would miss your
conference dinner and stay up late writing! There is certainly a
lot of hope and a lot of good news to look forward to. Justine.
3:28 PM, February 25, 2016
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